Cara Therapeutics specializes in the production of a new generation of drugs that help reduce acute pain, chronic pain and itching by acting on kappa-opioid receptors.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
CARA Therapeutics news
10.05.2022
The loss of CARA Therapeutics under GAAP for the 3 months of 2022 was $27.749 million, up 19.1% from $23.301 million in the previous year. Revenue increased 2.5 times to $4.79 million from $1.935 million a year earlier.
Source: 
ir.caratherapeutics.com
ir.caratherapeutics.com
28.04.2022
European Commission has approved Kapruvia, developed by Vifor Fresenius and Cara Therapeutics. Kapruvia is intended to treat itching associated with chronic kidney disease in adults on hemodialysis.
Source: ir.caratherapeutics.com
ir.caratherapeutics.com
02.03.2022
CARA Therapeutics reported a GAAP loss of $88.441 million for 2021, compared to a profit of $8.41 million in the previous year. Revenue decreased 5.9 times to $23.028 million from $135.082 million a year earlier.
Source: ir.caratherapeutics.com
ir.caratherapeutics.com
25.02.2022
CHMP has recommended approval of Kapruvia by Cara Therapeutics and VFMCRP. The drug is intended to treat moderate to severe pruritus associated with chronic kidney disease in patients on hemodialysis.
Source: ir.caratherapeutics.com
ir.caratherapeutics.com
General information
| Company name | CARA Therapeutics |
|---|---|
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 4 STAMFORD PLAZA 107 ELM STREET 9TH FLOOR STAMFORD CT 06902 203-406-3700 |
| Mailing address | 4 STAMFORD PLAZA 107 ELM STREET 9TH FLOOR STAMFORD CT 06902 |
| Website | www.caratherapeutics.com |
| Information disclosure | www.sec.gov |
English (US) 